SCHEMBL3430465

SCHEMBL3430465

O=c1ccc2ccc(F)c(O)c2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.60
CA9 Q16790 5/20 0.60
F11 P03951 1/20 0.41
CA1 P00915 1/20 0.38
CA3 P07451 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA13 Q8N1Q1 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
DAO P14920 5/20 0.37
DDO Q99489 2/20 0.37
ERN1 O75460 1/20 0.35
UPP1 Q16831 1/20 0.34
TNF P01375 1/20 0.34
RIPK1 Q13546 1/20 0.34
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL705402 0.81 CA12 (0.62) CA12CA9F11CA1CA3
SCHEMBL2820360 0.78 CA12 (0.58) CA12CA9F11CA1CA3
SCHEMBL30839765 0.78 CA12 (0.53) CA12CA9F11CA1CA3
SCHEMBL2819163 0.78 CA12 (0.58) CA12CA9F11CA1CA3
SCHEMBL4573974 0.78 CA12 (0.58) CA12CA9F11CA1CA3
SCHEMBL25003020 0.78 CA12 (0.53) CA12CA9F11CA1CA3
SCHEMBL4178782 0.75 CA12 (1.00) CA12CA9CA1CA3CA4
SCHEMBL3155040 0.73 CA12 (0.49) CA12CA9
SCHEMBL1977144 0.73 CA9 (0.44) CA12CA9CA1CA3CA4
SCHEMBL10412501 0.72 PDE3B (0.44) F11DAODDOPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257551-B1 AZATRICYCLIC ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2013-04-10 EP disclosed
US-8349828-B2 Azatricyclic antibiotic compounds ACTELION PHARMACEUTICALS LTD. (CH) 2013-01-08 US disclosed
US-20100331318-A1 AZATRICYCLIC ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2010-12-30 US disclosed
EP-2257551-A2 AZATRICYCLIC ANTIBIOTIC COMPOUNDS Actelion Pharmaceuticals Ltd. (CH) 2010-12-08 EP disclosed
WO-2009104147-A2 AZATRICYCLIC ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2009-08-27 WO disclosed
WO-2008120003-A1 SUBSTITUTED PIPERIDINES FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331318-A1 AZATRICYCLIC ANTIBIOTIC COMPOUNDS ZYX, AZI2, NAT1 CA12 3331/4885CA9 2907/4885F11 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.